#1 Clinical Trials Search in Europe

Study of Lutetium (177Lu) Vipivotide Tetraxetan and Ipilimumab for Men with Very High-Risk Prostate Cancer

1 1 1

What is this study about?

This clinical trial is focused on studying treatments for very high-risk prostate cancer. The study involves two treatments: 177-Lutetium-PSMA-617, a type of radioligand therapy, and Ipilimumab, an immunotherapy drug. The purpose of the study is to explore the feasibility and effectiveness of these treatments when used before surgery in men with this type of prostate cancer.

Participants in the study will receive either the radioligand therapy alone or in combination with the immunotherapy. The study will monitor the ability to perform surgery on the prostate after the treatment, as well as the response of the cancer to the treatment. The study will also track any side effects experienced by participants and how long they remain free from cancer progression after surgery.

The trial is expected to run until 2027, with recruitment starting in 2024. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatments. This study aims to provide valuable insights into new treatment options for men with very high-risk prostate cancer.

1 initial treatment phase

The treatment begins with the administration of Pluvicto, which contains the active substance lutetium (177lu) vipivotide tetraxetan. This is provided as a solution for injection or infusion.

The dosage and frequency of administration will be determined by the medical team based on individual patient needs and the study protocol.

2 combination therapy phase

In this phase, Ipilimumab is introduced. It is a concentrate for solution for infusion.

The combination of Pluvicto and Ipilimumab aims to enhance the treatment effect. The specific dosage and schedule will be provided by the healthcare provider.

3 monitoring and assessment phase

Throughout the treatment, regular monitoring will occur to assess the body’s response to the therapy. This includes blood tests and imaging studies.

The primary goal is to evaluate the feasibility of performing a prostatectomy on day 85, with a possible delay of up to 3 weeks if necessary.

4 surgical intervention phase

If the treatment is deemed feasible, a radical prostatectomy with pelvic lymph node dissection will be performed.

The surgery aims to remove the prostate and any affected lymph nodes to manage the cancer effectively.

5 post-surgery follow-up phase

After surgery, follow-up visits will be scheduled to monitor recovery and check for any signs of cancer recurrence.

The follow-up period includes monitoring for adverse events and assessing PSA progression-free survival for up to one year after the prostatectomy.

Who Can Join the Study?

  • Must be at least 18 years old.
  • If sexually active, must use a condom to prevent fathering a child and to prevent passing the study treatment to a partner through seminal fluid for at least 14 weeks after the last dose of the study medication.
  • Must have tumor tissue from both a prostate biopsy and a radical prostatectomy available for review by a specialist.
  • Must sign an informed consent form, which means you understand the study’s purpose and procedures and agree to participate.
  • Must have a confirmed diagnosis of prostate cancer with specific criteria: a very high-risk score called a Gleason Score of 4+4 or higher, a clinical stage called cT3, and either a positive clinical nodal status or a Serum-PSA level greater than 20 ng/ml.
  • Must not have cancer that has spread to other parts of the body, as shown by imaging tests.
  • Must not have received any previous treatment for prostate cancer.
  • Must have a performance status of 0-1 on the ECOG scale, which measures how well you can carry out daily activities.
  • Must be a candidate for a surgery called radical prostatectomy with pelvic lymph node dissection.
  • Must have a positive result on a specific imaging test called a PSMA PET scan, with a certain score.
  • Must meet specific laboratory criteria within 14 days before starting the study, including:
    • Bone Marrow: White blood cells, neutrophils, platelets, and hemoglobin levels must be within certain ranges.
    • Liver Function: AST/ALT and total bilirubin levels must be within certain limits.
    • Kidney Function: Serum creatinine must be within a specific range.
    • Thyroid Function: TSH levels must be normal, or further tests are needed if not.
    • Albumin: Must be above a certain level.
    • Electrolytes: Potassium and sodium levels must be within specific ranges.
    • Pancreatic Enzymes: Amylase and lipase levels must be within certain limits.
    • Blood Sugar: Must be below a specific level.

Who Cannot Join the Study?

  • Patients who do not have very high-risk prostate cancer as defined by specific medical criteria.
  • Patients who are not candidates for a surgery called radical prostatectomy, which involves removing the prostate gland and some surrounding tissue.
  • Patients who are not eligible for pelvic lymph node dissection, a procedure to remove lymph nodes in the pelvic area.
  • Patients who are female, as the study is only for male participants.
  • Patients who are part of a vulnerable population, meaning they might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Ukiqyetlqfnojbidhcaey Ejhrf Awv Essen Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not recruiting
30.09.2025

Trial locations

Investigated drugs:

177Lu-PSMA-617 is a type of targeted radiotherapy used in this trial. It is designed to deliver radiation directly to prostate cancer cells by binding to a specific protein found on the surface of these cells. This helps to destroy the cancer cells while minimizing damage to surrounding healthy tissue.

Ipilimumab is an immunotherapy medication used in this trial. It works by stimulating the body’s immune system to attack cancer cells. Ipilimumab blocks a specific protein that usually helps keep immune responses in check, allowing the immune system to better recognize and destroy cancer cells.

Investigated diseases:

Prostate Cancer – Prostate cancer is a disease where cells in the prostate gland grow uncontrollably. It often progresses slowly and may not show symptoms in the early stages. As it advances, it can lead to difficulties in urination, blood in urine, or pelvic discomfort. The disease can spread to nearby tissues or other parts of the body, such as bones and lymph nodes. The risk of developing prostate cancer increases with age, and it is more common in men over 50. Factors such as genetics and lifestyle may also influence its development.

Trial ID:
2024-514386-19-00
Protocol code:
CA184-608
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Finland France Germany Hungary +5

  • Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Greece Italy +3